Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
Yi‐Long Wu(Guangdong Academy of Medical Sciences), Qitao Yu(Guangxi Medical University), Bo Zhu(Huaian First People’s Hospital), Jia‐Lei Wang(Fudan University Shanghai Cancer Center), Guibin Qiao(St James's University Hospital), Jianchun Duan(Chinese Academy of Medical Sciences & Peking Union Medical College), Huiying Liang(Wuhan Union Hospital), Buhai Wang(Northern Jiangsu People's Hospital), Weizhi Chen(Genecast (China)), Jiuwei Cui(Jilin University), Congying Xie(Wenzhou Medical University), Shaokun Chuai(University of Pennsylvania), Ying Cheng(Jilin Province Tumor Hospital), Hai‐Yan Tu(Jiangnan University), Anwen Liu(Nanchang University), Xu‐Chao Zhang(Guangdong Academy of Medical Sciences), Xiao‐Yuan Chen(Fujian Provincial Cancer Hospital), Nong Yang(Central South University), Xiaorong Dong(The University of Melbourne), Mingfang Zhao(First Hospital of China Medical University), Panwen Tian(Sichuan University), Qing Zhou(Jiangnan University), Zhijie Wang(Hubei University of Medicine), Ming Chen(First Affiliated Hospital Zhejiang University), Hui Li(Fujian Medical University), Li Zhang(Gdańsk Medical University), Linghua Yan(Nanchang University), Yong Song(Nanjing General Hospital of Nanjing Military Command), Qibin Song(Wuhan University), Jun Zhao(Beijing Institute of Technology), Yun Fan(Zhejiang Cancer Hospital), Rongrong Chen(Annoroad Gene Technology (China)), Qinghua Zhou(Sichuan University), Yuan Chen(Fudan University Shanghai Cancer Center), Dongmei Lin(Chinese Academy of Medical Sciences & Peking Union Medical College), Ziming Li(Shanghai Jiao Tong University), Jiwei Liu(Mongolian University of Science and Technology), Penghui Zhou(Sun Yat-sen University), Cheng Huang(Army Medical University), Jian‐Ying Zhou(Sun Yat-sen University), Yunpeng Liu(Shenyang Institute of Automation), Xiao‐Nan Wang(Dalian Medical University), Xiaoqing Liu(Chinese PLA General Hospital), Zheng‐Fei Zhu(Nanjing General Hospital of Nanjing Military Command), Chengping Hu(Central South University), Shun Lü(Shanghai Jiao Tong University), Lv‐Hua Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Gen Lin(Fujian Medical University)
Cited by 8
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k